دورية أكاديمية
Development of cardioplegic solution without potassium: experimental study in rat.
| العنوان: | Development of cardioplegic solution without potassium: experimental study in rat. |
|---|---|
| المؤلفون: | Reichert K, Carmo HR, Lima F, Torina AG, Vilarinho KA, Oliveira PP, Silveira Filho LM, Severino ES, Petrucci O |
| المصدر: | Revista brasileira de cirurgia cardiovascular : orgao oficial da Sociedade Brasileira de Cirurgia Cardiovascular [Rev Bras Cir Cardiovasc] 2013 Oct-Dec; Vol. 28 (4), pp. 524-30. |
| نوع المنشور: | Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Sociedade Brasileira de Cirurgia Cardiovascular Country of Publication: Brazil NLM ID: 9104279 Publication Model: Print Cited Medium: Internet NLM ISO Abbreviation: Rev Bras Cir Cardiovasc Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: São Paulo, SP, Brasil : Sociedade Brasileira de Cirurgia Cardiovascular |
| مواضيع طبية MeSH: | Cardioplegic Solutions/*pharmacology , Heart/*drug effects , Heart Arrest, Induced/*methods , Organ Preservation/*methods, Adenosine Triphosphate/analysis ; Animals ; Cardioplegic Solutions/chemistry ; Caspase 3/analysis ; Cell Survival/drug effects ; Glucose/chemistry ; Glucose/pharmacology ; Mannitol/chemistry ; Mannitol/pharmacology ; Models, Animal ; Myocardial Reperfusion Injury/prevention & control ; Potassium/chemistry ; Potassium/pharmacology ; Potassium Chloride/chemistry ; Potassium Chloride/pharmacology ; Procaine/chemistry ; Procaine/pharmacology ; Rats ; Rats, Wistar ; Reproducibility of Results ; Sodium Channel Blockers/chemistry ; Time Factors |
| مستخلص: | Introduction: Myocardial preservation during open heart surgeries and harvesting for transplant are of great importance. The heart at the end of procedure has to resume its functions as soon as possible. All cardioplegic solutions are based on potassium for induction of cardioplegic arrest. Objective: To assess a cardioplegic solution with no potassium addition to the formula with two other commercially available cardioplegic solutions. The comparative assessment was based on cytotoxicity, adenosine triphosphate myocardial preservation, and caspase 3 activity. The tested solution (LIRM) uses low doses of sodium channel blocker (lidocaine), potassium channel opener (cromakalin), and actin/myosin cross bridge inhibitor (2,3-butanedione monoxime). Methods: Wistar rats underwent thoracotomy under mechanical ventilation and three different solutions were used for "in situ" perfusion for cardioplegic arrest induction: Custodiol (HTK), Braile (G/A), and LIRM solutions. After cardiac arrest, the hearts were excised and kept in cold storage for 4 hours. After this period, the hearts were assessed with optical light microscopy, myocardial ATP content and caspase 3 activity. All three solutions were evaluated for direct cytotoxicity with L929 and WEHI-164 cells. Results: The ATP content was higher in the Custodiol group compared to two other solutions (P<0.05). The caspase activity was lower in the HTK group compared to LIRM and G/A solutions (P<0.01). The LIRM solution showed lower caspase activity compared to Braile solution (P<0.01). All solutions showed no cytotoxicity effect after 24 hours of cells exposure to cardioplegic solutions. Conclusion: Cardioplegia solutions without potassium are promised and aminoacid addition might be an interesting strategy. More evaluation is necessary for an optimal cardioplegic solution development. |
| References: | Br J Pharmacol. 1990 Jan;99(1):169-75. (PMID: 2184910) Circ Res. 1975 Apr;36(4):481-9. (PMID: 1116243) Surgery. 1953 Jan;33(1):52-9. (PMID: 13015312) Am J Physiol. 1995 Mar;268(3 Pt 2):H1239-48. (PMID: 7900878) Ann Thorac Surg. 1999 Nov;68(5):1988-94. (PMID: 10585117) Pflugers Arch. 1979 Mar 16;379(2):137-42. (PMID: 571107) Ann Thorac Surg. 1992 Nov;54(5):852-9; discussion 859-60. (PMID: 1417275) Lancet. 1955 Jul 2;269(6879):21-2. (PMID: 14382605) Pharmacol Ther. 2010 Jul;127(1):41-52. (PMID: 20398698) Rev Bras Cir Cardiovasc. 2008 Apr-Jun;23(2):224-34. (PMID: 18820786) Cardiology. 2011;120(2):73-83. (PMID: 22143256) Am J Physiol Heart Circ Physiol. 2009 Jun;296(6):H1705-20. (PMID: 19363132) Ann Thorac Surg. 1994 Jul;58(1):7-13. (PMID: 8037563) Ann Thorac Surg. 1997 May;63(5):1353-60. (PMID: 9146327) Eur J Cardiothorac Surg. 2013 Mar;43(3):526-31. (PMID: 22665382) J Physiol. 1975 Sep;251(1):1-59. (PMID: 1185607) J Cardiovasc Surg (Torino). 1996 Jun;37(3):269-74. (PMID: 8698763) Eur J Cardiothorac Surg. 2011 Aug;40(2):352-9. (PMID: 21242090) Am J Physiol. 1993 Dec;265(6 Pt 2):H2017-26. (PMID: 8285240) Cell Biochem Funct. 2006 Sep-Oct;24(5):413-8. (PMID: 16142696) J Thorac Cardiovasc Surg. 2011 Dec;142(6):1552-61. (PMID: 21742347) J Heart Lung Transplant. 2008 Feb;27(2):208-16. (PMID: 18267229) Acta Histochem. 2012 Dec;114(8):785-96. (PMID: 22341561) Curr Opin Pharmacol. 2009 Apr;9(2):220-6. (PMID: 19492439) |
| المشرفين على المادة: | 0 (Bretschneider cardioplegic solution) 0 (Cardioplegic Solutions) 0 (Sodium Channel Blockers) 3OWL53L36A (Mannitol) 4Z8Y51M438 (Procaine) 660YQ98I10 (Potassium Chloride) 8L70Q75FXE (Adenosine Triphosphate) EC 3.4.22.- (Casp3 protein, rat) EC 3.4.22.- (Caspase 3) IY9XDZ35W2 (Glucose) RWP5GA015D (Potassium) |
| تواريخ الأحداث: | Date Created: 20140307 Date Completed: 20140930 Latest Revision: 20211021 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC4389432 |
| DOI: | 10.5935/1678-9741.20130085 |
| PMID: | 24598959 |
| قاعدة البيانات: | MEDLINE |
| DOI: | 10.5935/1678-9741.20130085 |
|---|